Actively Recruiting
COMS for Chronic Ulcers Treatment
Led by Sebastian Probst · Updated on 2026-05-08
122
Participants Needed
10
Research Sites
52 weeks
Total Duration
On this page
Sponsors
S
Sebastian Probst
Lead Sponsor
M
Medical University of Vienna
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. These ulcers often result from macro- and microvascular disorders, the most common being chronic venous insufficiency (CVI), alone or with peripheral artery disease (PAD) or microangiopathy. Despite different causes, chronic vascular-origin wounds share similar biological traits and require the same physiological processes for healing. Vascular issues hinder blood perfusion, reducing oxygen, nutrients, and growth factors, leading to decreased energy metabolism and impaired cell functions necessary for proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Reduced blood supply also limits leukocyte function, compromising the immune response and leading to persistent inflammation and infection. Consequently, these wounds cannot effectively heal, showing prolonged inflammation, persistent infections, and cellular senescence. Best practice wound care includes compression therapy and physical activity for venous ulcers, and angioplasty, surgery, or bypass for arterial ulcers. These treatments aim to improve blood flow, reduce venous stasis, and enhance venous return. Compression therapy and physical activity lower hydrostatic pressure in the lower limb, while angioplasty and surgery remove arterial blockages or create new blood flow routes. Recent studies highlight the role of mechano-sensitive (MS) ion channels in skin cell processes and their dysfunction in dermatological disorders. Magnetic stimulation can activate MS TRCP1 channels, enhancing mitochondrial respiration and mitochondriogenesis via the Ca2+/CalModulin(CaM)/NFAT/PGC-1α pathway. Ca2+-activated calmodulin also catalyzes nitric oxide (NO), promoting vasodilation and tissue perfusion. Bimodal red and near-infrared photobiomodulation can further increase mitochondrial respiration and ATP production by activating Cytochrome C oxidase and mitigating NO-induced downregulation. This synergistic mechanism of concurrent optical and magnetic stimulation (COMS) may amplify Ca2+ and NO-mediated processes like cell proliferation, migration, vasodilation, and angiogenesis while resolving inflammation. Thus, COMS may offer a promising therapy for chronic, inflammation-prone wounds. The effectiveness of COMS has yet to be validated in large-scale studies. This proposal aims to assess the impact of COMS therapy combined with standard care versus standard care alone on healing, wound closure, recurrence, pain, quality of life, economic outcomes, and device usability in patients with venous leg ulcers (VLU) and VLU associated with PAD in a large-scale multicentric randomized controlled trial.
CONDITIONS
Official Title
COMS for Chronic Ulcers Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Clinical diagnosis of venous leg ulcer (VLU) or VLU with peripheral arterial disease (PAD)
- Ankle-brachial index (ABI) between 0.5 and 1.3 or ankle pressure greater than 60 mmHg
- Ulcer size between 2 and 50 cm² after debridement at screening
- Ulcer duration longer than 30 days and less than 2 years
- For patients with diabetes, HbA1c of 12% or less at screening
- Able and willing to provide written informed consent prior to study procedures
You will not qualify if you...
- Pregnant or breastfeeding
- Malignancy in the ulcer area
- Use of photosensitizing medication within 30 days
- Severe immunosuppression, including chronic corticosteroid use over 10 mg/day prednisolone equivalent
- NYHA class III or IV heart failure
- End-stage renal disease requiring dialysis
- Ulcer area reduction greater than 30% during run-in phase
- Active infection requiring systemic antibiotics at baseline
- Use of advanced wound therapies within 2 weeks prior to screening (e.g., negative pressure wound therapy, skin substitutes, hyperbaric oxygen)
- Participation in another interventional clinical trial within 30 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Medizinische Universität Graz
Graz, Austria
Not Yet Recruiting
2
Medizinische Universität Wien
Vienna, Austria
Not Yet Recruiting
3
Augustines's Clinic
Malestroit, France
Not Yet Recruiting
4
Universitätsklinikum Essen
Essen, Germany
Not Yet Recruiting
5
University Clinic Hamburg-Eppendorf
Hamburg, Germany
Not Yet Recruiting
6
Jura Hospital
Delémont, Switzerland
Not Yet Recruiting
7
Venenklinik Bellevue
Kreuzlingen, Switzerland
Actively Recruiting
8
Cité Générations
Onex, Switzerland
Not Yet Recruiting
9
Spital Thun
Thun, Switzerland
Not Yet Recruiting
10
University Hospital
Zurich, Switzerland
Not Yet Recruiting
Research Team
S
Sebastian Probst, Prof. Dr.
CONTACT
C
Camille Saini, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here